RTX-700 (Resonant Therapeutics, Inc.)

RTX-700 is a preclinical antibody-based therapeutic candidate being developed by Resonant Therapeutics. It is designed to target an undisclosed inflammation regulator within the tumor microenvironment to treat solid tumors, specifically kidney cancer and lung cancer. The candidate was identified using Resonant's proprietary discovery platform, which focuses on identifying novel, functionally relevant targets that drive tumor progression and immune evasion. While the specific molecular target remains proprietary, the therapeutic approach aims to modulate inflammatory signaling pathways to inhibit tumor growth and potentially enhance anti-tumor immune responses.